Clinical Trial Detail

NCT ID NCT02199223
Title Regorafenib + Panitumumab
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors University of Utah
Indications

colorectal cancer

Therapies

Panitumumab + Regorafenib

Age Groups: adult

No variant requirements are available.